Robert (Bob) A. Elliott
Chairman
Elliott Investment Company

Bob Elliott is currently Chairman of Elliott Investment Company, Newport Beach, California. Elliott Investment Company specializes in investments in selected device start-up ventures, as well as providing consulting services to such start-ups.

Prior to founding his own company, Bob was the Chairman and CEO of VLI Corporation, Irvine, California. VLI was the manufacturer and worldwide marketer of the Today Vaginal Contraceptive Sponge and other personal care products. VLI was sold to American Home Products in 1987. Prior to joining VLI, Bob was Vice President of Howmedica, Incorporated, a wholly owned subsidiary of Pfizer. Before joining Howmedica, Bob was President and CEO of Shiley, Inc. a major worldwide supplier of cardiovascular and respiratory care products. Shiley was sold to Pfizer in 1980.

Bob has been a Director of Intermark, Inc., Triton, Inc., RemedyTemp, Inc. and the Rusty Pelican Restaurants. He has also invested in and/or was a Director in numerous private medical device companies including: Denar, Steri-Oss Dental, CareCredit, Advanced Surgical Intervention, Woodruff Laboratories and Polymer Technology Group. Bob is also a member of the Board of Trustees of Chapman University and a member of the University of Southern California Athletic Department Board of Counselors.

Bob holds a B.S. Degree in Marketing from California State University and an MBA from the University of Southern California.

 

J. Neal Armstrong, CPA

Mr. Armstrong joined Aspect Medical Systems, Inc. in 1996 and served as Vice President, Chief Financial Officer, Secretary and Treasurer until January 2005 when he retired as an officer of Aspect. Mr. Armstrong currently serves on the board of directors for deCode Genetics, Salient Surgical, TransMedics and VapoTherm. From 1990 to 1996, Mr. Armstrong served as Vice President of Finance, Chief Financial Officer and as a director of Haemonetics, Inc., a manufacturer of blood processing systems. From 1985 to 1990, he was the Vice President of Finance and Administration, Treasurer and Chief Financial Officer at BTU International, Inc., a manufacturer of thermal processing systems. Prior to 1985, he served for 14 years in various senior operating and financial positions at Texas Instruments, Inc., an electronics company. Mr. Armstrong holds a Bachelor degree in accounting from the University of Texas and is a Certified Public Accountant.

 

Eitan Konstantino, Ph.D
President and CEO
Trireme Medical, Inc.

President & CEO, founder, Trireme Medical Inc. (TMI), developer of novel stent system for the treatment of coronary bifurcations. Prior to starting TMI, Dr. Konstantino co-founded AngioScore Inc. Dr. Konstantino is the main inventor of the AngioSculpt catheter and the Easy Exchange delivery system and was the president and chief scientist of AngioScore from its inception to late 2006. Previously, Dr. Konstantino was the CEO & COO of Advanced Stent Technologies (AST), a bifurcation stent company that was acquired by Boston Scientific in 2004, and co-invented the Petal bifurcation stent that is currently in development with Boston Scientific. Prior to AST, he was Chief Technical Officer of Bypass Ltd, a developer of nitinol anastomotic devices for minimally invasive heart surgery. Dr. Konstantino graduated from the Technion, Israel’s premier engineering school and is the co-chairman of the ASTM F04.30.06 Cardiovascular standards task group.

 

Thomas A. Raffin, M.D.
Co-Founder & Partner
Telegraph Hill Partners

Thomas A. Raffin, M.D. Co-Founder and General Partner in Telegraph Hill Partners, a life sciences and health care private equity firm in San Francisco www.thpartners.net Tom has spent 27 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. Over the past decade he has worked extensively in the healthcare and medical device sectors and is co-founder of Rigel Pharmaceuticals. Currently, Tom is a director of AngioScore, Confirma, Freedom Innovations, LDR, NewLink Genetics, PneumRx and is an advisor to numerous other companies. He is an active investigator, and has written over 200 publications. Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and medical residency at Harvard.

 

Benjamin S. Schapiro
Founder & Partner
QuestMark Partners

In 1966, Ben began his career in investment banking at Robert Garrett & Sons, which merged into Alex. Brown & Sons in 1974. Throughout his 32-year tenure, his efforts encompassed institutional, international and private client accounts, real estate finance, corporate finance, merger and acquisition transactions as well as public and private investing in emerging growth companies. In 1998, he left Alex. Brown to organize QuestMark Partners with the original investment criteria and objectives that exist today. He has served as chairman, vice chairman and trustee or board member of a number of endowment funds, charitable organizations and professionally managed portfolios. Ben graduated from Randolph-Macon College in 1964 with a degree in Economics.

Ben currently is or has been a member or active observer on the boards of Align Technology (ALGN), AngioScore, Aspect Medical Systems (ASPM), eHealth (EHTH), GeneOhm Sciences (BDX), GenVault, Hospital Partners of America, Nimblefish, SeniorHealth, TissueLink Medical, Vapotherm and Xirrus.

 

Lisa Suennen
Managing Member
Psilos Group Managers

Ms. Suennen is a co-founder and Managing Member of Psilos Group, a healthcare-focused venture capital firm with over $550 million under management. Ms Suennen has headed Psilos' West Coast office since the firm's founding in 1988 and focuses on the medical device, healthcare information technology and healthcare services sectors. She serves as a Director of several Psilos portfolio companies, including AngioScore, Inc. (chairman), VeraLight, Inc (chairman), InSound Medical, Inc., IntelliDOT Corp., and Navitas Cancer Services (chairman). Prior to Psilos, Ms. Suennen spent 9 years at Merit Behavioral Care where she held various senior executive roles from its start-up days until its sale for $800 million to Magellan in 1998. She previously worked in the high technology field at Ingres, X/Open and Regis McKenna, Inc. Ms. Suennen holds graduate and undergraduate degrees from the University of California, Berkeley where she now sits on the National Advisory Board of the Institute for Governmental Studies.

 

Thomas R. Trotter
President & Chief Executive Officer
AngioScore, Inc.

Thomas R. Trotter joined AngioScore in August 2005 as President and CEO.

Mr. Trotter brings to AngioScore more than 30 years experience in the medical device business. Most recently, he served as President and CEO of OrthoLogic, Inc., a public orthopedics company. Prior to OrthoLogic, Mr. Trotter worked for Mallinckrodt, Inc. as President of the Critical Care Division, which included 2500 employees and over $400 million in annual revenues. He joined Mallinckrodt via the acquisition of Diamond Sensor Systems, a venture-backed medical device company in the blood chemistry analysis business, where he served as President and CEO. Previously, Mr. Trotter worked for Shiley, Inc., then a division of Pfizer, where he managed the worldwide cardiopulmonary business.

Mr. Trotter holds an MBA from Pepperdine University and a B.S. in business administration from the University of Maryland. He is also a senior fellow of the Holmes Society at Harvard University.

 

Jeanette M. Welsh
Principal
Telegraph Hill Partners

Ms. Welsh has spent 17 years in the areas of private equity, mergers & acquisitions, securities law and administration. She is currently a Principal at Telegraph Hill Partners, a life sciences and health care private equity firm in San Francisco. Prior to joining THP, Ms. Welsh worked at Three Cities Research, a private equity firm in New York focused on middle market companies. Her private equity investment activities range from growth equity and leveraged buyouts to going private transactions and bankruptcy auctions. Prior to joining Three Cities Research, Jeanette practiced law at Epstein, Becker & Green P.C. in New York where she focused on corporate and securities law. Before commencing her legal career, Jeanette was part of the M&A department of Société Générale Securities Corporation. She is currently a director of Interface Associates and AngioScore. Jeanette has a Bachelor of Art degree in Philosophy from Hunter College, City University of New York and a Juris Doctor from Fordham University School of Law.